An Experimental Treatment for FSHD Has Been Awarded Fast Track Designation by the FDA
Acceleron Pharma has just received Fast Track designation from the US Food and Drug Administration (FDA) for their experimental treatment ACE-083 designed to treat patients with facioscapulohumeral muscular dystrophy (FSHD).…